NASDAQ:MBIO Mustang Bio (MBIO) Stock Price, News & Analysis $0.51 -0.02 (-3.69%) As of 09/23/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesOwnershipSEC Filings About Mustang Bio Stock (NASDAQ:MBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mustang Bio alerts:Sign Up Key Stats Today's Range$0.49▼$0.5550-Day Range$0.49▼$0.6552-Week Range$0.47▼$1.85Volume24,094 shsAverage Volume24,910 shsMarket Capitalization$3.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for cancer and rare genetic diseases. The company’s work centers on engineered immune-cell therapies designed to recognize and destroy cancer cells, as well as genetic medicines intended to address underlying disease causes. Mustang’s investigational programs have included MB-106, a CD20-targeted chimeric antigen receptor T-cell (CAR-T) therapy being developed for certain B-cell malignancies, and MB-101, an IL13Rα2-targeted CAR-T therapy being studied for glioblastoma and other solid tumors. These candidates have been evaluated in clinical studies, but they are investigational and have not been established as approved treatments. Mustang Bio was founded in 2015 and has operated as a biotechnology company affiliated with Fortress Biotech. The company has maintained research, development and manufacturing operations in the United States, including a cell- and gene-therapy manufacturing facility in Worcester, Massachusetts. Its therapies have been developed through internal research and collaborations with academic and clinical institutions.AI Generated. May Contain Errors. Read More Mustang Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreMBIO MarketRank™: Mustang Bio scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingMustang Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMustang Bio has only been the subject of 1 research reports in the past 90 days.Read more about Mustang Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mustang Bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mustang Bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMustang Bio has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Mustang Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.76% of the float of Mustang Bio has been sold short.Short Interest Ratio / Days to CoverMustang Bio has a short interest ratio ("days to cover") of 3.55, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mustang Bio has recently increased by 4.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMustang Bio does not currently pay a dividend.Dividend GrowthMustang Bio does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Mustang Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mustang Bio insiders have not sold or bought any company stock.Percentage Held by Insiders4.00% of the stock of Mustang Bio is held by insiders.Percentage Held by Institutions9.95% of the stock of Mustang Bio is held by institutions.Read more about Mustang Bio's insider trading history. Receive MBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBIO Stock News HeadlinesMindBio Completes Manufacture and Delivery of First Prototype Edge AI Intoxication and Fatigue Detection KiosksJune 9, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment SolutionMay 14, 2026 | globenewswire.comElon’s AI Phone is comingRumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.May 12, 2026 | globenewswire.comMindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication DetectionMay 12, 2026 | globenewswire.comMustang Bio Inc.July 25, 2025 | barrons.comTalisker Receives Assay Results from 1105 Level Lateral Development at the Mustang MineJuly 24, 2025 | globenewswire.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - NasdaqJuly 10, 2025 | nasdaq.comSee More Headlines MBIO Stock Analysis - Frequently Asked Questions How have MBIO shares performed this year? Mustang Bio's stock was trading at $0.9810 at the beginning of the year. Since then, MBIO stock has decreased by 47.9% and is now trading at $0.5114. How were Mustang Bio's earnings last quarter? Mustang Bio, Inc. (NASDAQ:MBIO) announced its earnings results on Wednesday, August, 5th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($140.00) by $139.84. When did Mustang Bio's stock split? Shares of Mustang Bio reverse split on the morning of Thursday, January 16th 2025.The 1-50 reverse split was announced on Tuesday, January 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are Mustang Bio's major shareholders? Mustang Bio's top institutional shareholders include BlackRock Inc. (1.12%). Insiders that own company stock include Adam J Chill and David Jin. View institutional ownership trends. How do I buy shares of Mustang Bio? Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mustang Bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/05/2026Today9/24/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 8 days, MBIO's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MBIO CIK1680048 Webwww.mustangbio.com Phone(781) 652-4500FaxN/AEmployees4Year Founded2015Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.23% Return on Assets-17.55% Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.39Miscellaneous Outstanding Shares7,580,000Free Float7,274,000Market Cap$3.88 million OptionableNot Optionable Beta2.05 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MBIO) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
